CTLA4 and neoplasm: Immunotherapy specifically activates the anti-tumor activity of T lymphocytes by blocking the interactions between PD-1, PD-L1, and CTLA-4, thereby enabling T cells to specifically recognize and eliminate tumor cells while sparing normal tissues (26, 27).